The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

Millions of Medicare enrollees are likely to see relief in 2025 when a $2,000 cap on out-of-pocket prescription drug-spending ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Washington researchers and care providers are struggling to keep up with new chemicals in the region’s illicit drug supply.